Author's response to reviews

Title: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

Authors:

Elsayed Z Soliman (esoliman@wfubmc.edu)
Shanthi Mendis (mendiss@who.int)
Wasantha P Dissanayake (wdissana@dialogsl.net)
Noel P Somasundaram (noelsomasundaram@gmail.com)
Padma S Gunaratne (pagunara@hotmail.com)
I Kumudini Jayasingne (kumujay@googlemail.com)
Curt D Furberg (cfurberg@wfubmc.edu)

Version: 6 Date: 6 December 2010

Author's response to reviews: see over
Ref# 4748862633961545

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

Dear Editor-In-Chief, the Trials journal

We appreciate your favorable decision and the opportunity to improve and resubmit our manuscript. Please find below, our response to the reviewers’ comments. As suggested by the reviewer, we have replaced our original conclusion with the conclusion he suggested. We hope this revision meets your final acceptance.

Sincerely,

Curt D Furberg MD, PhD
Division of Public Health Sciences
Wake Forest University School of Medicine
Medical Center Boulevard
Winston-Salem, NC  27157-1063
Phone:  (336) 716-3730
FAX:  (336) 716-5425
Reviewer's report:
The authors have addressed all the major issues and no further major revisions are required.

Response:
Thanks. No action required

One essential minor revision is needed to the Conclusion of the Abstract, which incorrectly states that "we failed to document the anticipated risk factor reductions with the Polypill". Risk factor reductions were documented on the Polypill but it was not possible to quantify these because the control group received similar treatment. I would suggest the following Conclusion in place of the existing one.
"We successfully completed a Polypill feasibility trial in Sri Lanka. We were able to document high acceptability of the Polypill to patients and physicians. We were unable to estimate the risk factor reductions on the Polypill because the control group received similar treatment with individual drugs. The Polypill was however simpler and achieved comparable risk factor reductions, highlighting its potential usefulness in the prevention of CVD"

Response:
We have replaced our original conclusion in the abstract (page 2) and the text (page 12) with the conclusion suggested by the reviewer.